Free Trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Teachers Retirement System of The State of Kentucky

Teva Pharmaceutical Industries logo with Medical background

Teachers Retirement System of The State of Kentucky increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 10.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,894,100 shares of the company's stock after purchasing an additional 184,100 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.17% of Teva Pharmaceutical Industries worth $29,112,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth approximately $44,000. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $39,000. Compagnie Lombard Odier SCmA acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth approximately $54,000. Finally, Quadrant Capital Group LLC lifted its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after acquiring an additional 949 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $0.24 during midday trading on Wednesday, hitting $16.53. The stock had a trading volume of 5,621,256 shares, compared to its average volume of 10,326,268. The firm's fifty day moving average is $16.98 and its two-hundred day moving average is $16.87. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market capitalization of $18.95 billion, a PE ratio of -14.36, a P/E/G ratio of 0.96 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company's revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.55% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Finally, Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $24.71.

View Our Latest Research Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines